2023-2034年:美国NTM感染市场预计将从3.6亿美元增长到8.6亿美元,主要是因病例增加,治疗选择改善和新疗法. 2023-2034: U.S. NTM infection market estimated to grow from $360M to $860M, driven by rising cases, improved treatment options, and new therapies.

美国非结核病菌菌感染的市场预计将从2023年的3.6亿美元增长到2034年的8.6亿美元,复合年增长率为13.4%。 The U.S. market for nontuberculous mycobacterial (NTM) infections is expected to grow from $360 million in 2023 to $860 million by 2034, with a compound annual growth rate of 13.4%. 增加的原因是非治疗性药物病例增加,治疗选择(包括ARIKAYCE等药物)的改进,以及正在发展新的疗法。 The increase is attributed to rising NTM cases, improvements in treatment options—including drugs like ARIKAYCE—and ongoing development of new therapies. 2023年,美国约有108 000例经诊断的NTM病例,由于各种健康因素,这一数字预计会上升。 In 2023, there were approximately 108,000 diagnosed NTM cases in the U.S., a number projected to rise due to various health factors.